Join ViewRay for a multi-disciplinary, multi-institutional webinar uniting some of the best and brightest minds in pancreatic cancer care from the U.S. and U.K. We’ll hear from experts committed to advancing care, offering new treatment options, extending life, and sustaining the quality of life.

• Staging Pancreas Cancer: A Surgeon’s Perspective – Dr. Keith Roberts, a consultant HPB Surgeon, University of Birmingham School of Cancer Sciences, will share an overview of cutting-edge surgical options for pancreatic cancer, including a look at borderline resectable cases and the role of radiation in improving outcomes.

• The U.S. Experience Treating Pancreas Cancer on MRIdian – Dr. Michael Bassetti, University of Wisconsin, will share his expertise in SBRT treatment for patients with unresectable disease.

• University of Oxford/GenesisCare – Dr. James Good, Clinical Director of Stereotactic Radiotherapy at GenesisCare, will share an overview of their UK MRIdian SBRT program as well as their groundbreaking collaboration to provide treatment at no cost to eligible NHS pancreatic cancer patients.

• MRIdian Vision Presentation – Dr. James F. Dempsey, ViewRay Inc., will share his vision of MRgRT technology and some possible futures for MRIdian

Don’t miss this exciting event.
Consultant Hepatobiliary, Pancreatic and Liver Transplant Surgeon, University Hospitals Birmingham
Mr. Roberts is a consultant liver transplant and HPB surgeon at University Hospitals Birmingham. His research focuses on improving surgery and the patient pathway for pancreatic cancer treatment. He is the pancreatic surgical specialty lead for the Royal College of Surgeons of England and honorary treasurer for the Pancreatic Society of Great Britain and Ireland. In 2018 he led the UK's largest audit of pancreatic cancer treatment, RICOCHET. Data from that audit is presently being analyzed and will help shape improvements across the country.
Associate Professor, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health
Dr. Bassetti is an Associate Professor of Radiation Oncology at the University of Wisconsin, Madison, and a member of the Carbone Cancer Center. He was born in Seattle, Washington and graduated from the University of Washington. After graduation, Dr. Bassetti worked in the biotech industry and in the University of Washington Department of Immunology where he fostered a strong interest in medicine and immunology. In 2008, Dr. Bassetti obtained his combined medical and doctoral degrees as part of the Medical Scientist Training Program at the University of Colorado Health Sciences Center. He then completed his medical internship in Internal Medicine and residency in Radiation Oncology at the University of Michigan. He joined the faculty at the University of Wisconsin, Madison in 2013. Dr. Bassetti’s clinical and research work focuses on the treatment of gastrointestinal (GI) and lung cancers. He is actively involved in clinical trials for these disease sites, exploring the use of MRI-guided radiation and immunotherapy.
Clinical Director of Stereotactic Radiotherapy
Dr. Good is a head/neck and GI oncologist at the Queen Elizabeth Hospital in Birmingham. He has a particular clinical and research focus on SBRT for hepatocellular and pancreatic cancers and immunotherapy trials. He sits on the committee of the UK SABR Consortium. James leads the GenesisCare MRIdian program and works closely with colleagues at the Oxford Institute of Radiation Oncology on research and innovation in MR-guided radiotherapy.
ViewRay, Chief Science Officer
Company founder and inventor of the ViewRay technology, Jim Dempsey guides the scientific and technical aspects of the MRIdian system's development.